The 2019 REstart or STop Antithrombotics Randomised Trial (RESTART) study found that aspirin therapy after ICH did not increase the risk of recurrent bleeding during a 2-year follow-up period and showed a trend toward reducing rebleeding, potentially related to aspirin’s anti-inflammatory effects [ 159 ].
← all excerpts
Postoperative Rebleeding: The Sword of Damocles in Minimally Invasive Surgery for Intracerebral Hemorrhage.
1
—
—